Xinwei Medical (06609) Guides H1 Revenue of RMB 280M+ on 50%+ Growth, Adjusted Net Profit Doubles

According to Zhitong Finance, Xinwei Medical Co., Ltd. (06609) on July 21 guided first-half 2026 revenue of at least RMB 280 million, representing growth exceeding 50% year-over-year, with net profit projected at over RMB 60 million and adjusted net profit of over RMB 70 million, up more than 100% year-over-year. The company attributed the acceleration to rising clinical adoption and market penetration of core products in ischemic stroke, hemorrhagic stroke, and vascular closure segments, coupled with expanded hospital coverage and improved operational efficiency.
Disclaimer: The information on this page may come from third-party sources and is for reference only. It does not represent the views or opinions of Gate and does not constitute any financial, investment, or legal advice. Virtual asset trading involves high risk. Please do not rely solely on the information on this page when making decisions. For details, see the Disclaimer.
Comment
0/400
No comments